clinical trial · NCT06584032
Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
Hutchmed·phase3·recruiting·n = 412
Advanced Endometrial Cancerfruquintinibsintilimabpaclitaxeldoxorubicin
brief summary
The goal of this study is to evaluate whether fruquintinib(HMPL-013) plus sintilimab(IBI308) is safe and effective in the treatment of advanced endometrial cancer(EMC).
started
Dec 12, 2024
primary completion
Jan 8, 2029
completion
Jun 9, 2029
last updated
Jan 7, 2025
detailed description
A randomized, open, positive-controlled, multicenter Phase III clinical study to compare the efficacy and safety of fruquintinib(HMPL-013) plus sintilimab(IBI308) versus chemotherapy in patients with advanced endometrial cancer who have progressed after first-line standard chemotherapy
official title
A Randomized,Open-label,Multicenter Phase III Clinical Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab Versus Chemotherapy of the Treating Physician's Choice as Second-line Treatment for Advanced Endometrial Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol